Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; and hemodiafilters for use as dialyzers in an hemodialysis treatment, as well as other disposables for use in the hemodiafiltration treatment process. The company was founded in 1997 and is headquartered in South Orange, New Jersey.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone201-343-5202
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.69 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable
Nephros (OTCMKTS:NEPH) Frequently Asked Questions
What is Nephros' stock symbol?
Nephros trades on the OTCMKTS under the ticker symbol "NEPH."
How were Nephros' earnings last quarter?
Nephros, Inc. (OTCMKTS:NEPH) posted its earnings results on Tuesday, March, 12th. The company reported ($0.01) earnings per share for the quarter. The firm had revenue of $1.61 million for the quarter. Nephros had a negative net margin of 59.82% and a negative return on equity of 75.94%. View Nephros' Earnings History.
When is Nephros' next earnings date?
Has Nephros been receiving favorable news coverage?
News articles about NEPH stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Nephros earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Nephros' key competitors?
Some companies that are related to Nephros include Ekf Diagnostics (EKF), ASLAN PHARMACEU/ADR (ASLN), Capital Senior Living (CSU), Galmed Pharmaceuticals (GLMD), Aptinyx (APTX), Tristel (TSTL), Stereotaxis (STXS), Surface Oncology (SURF), Harrow Health (HROW), Zomedica Pharmaceuticals (ZOM), Eton Pharmaceuticals (ETON), Concord Medical Services (CCM), Syndax Pharmaceuticals (SNDX), Organovo (ONVO) and XOMA (XOMA).
What other stocks do shareholders of Nephros own?
Who are Nephros' key executives?
Nephros' management team includes the folowing people:
- Mr. Daron G. Evans, Pres, CEO & Director (Age 45)
- Mr. Andrew Astor, CFO & COO (Age 62)
- Ms. Joleen C. Turner, VP of Marketing & Bus. Devel.
How do I buy shares of Nephros?
Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nephros' stock price today?
One share of NEPH stock can currently be purchased for approximately $0.5440.
How big of a company is Nephros?
Nephros has a market capitalization of $35.15 million and generates $5.69 million in revenue each year.
What is Nephros' official website?
How can I contact Nephros?
Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201-343-5202.
MarketBeat Community Rating for Nephros (OTCMKTS NEPH)
MarketBeat's community ratings are surveys of what our community members think about Nephros and other stocks. Vote "Outperform" if you believe NEPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
